Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Nanobiotix S.A. - Sponsored ADR NBTX

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
12.02%

Capital & Financial Ratios

Market Cap
1,780.00
Revenue
0.10
Net Income
(130.50)
Free Cash Flow
(87.24)
Net Debt
(59.68)
Current Ratio
1.09
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
14,920.38
P/B ratio
0.00
Past 5Y EPS Growth
9.96%
This Y EPS Growth
22.18%
Next Y EPS Growth
(11.67%)
Next 5Y EPS Growth
30.10%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—

Assets vs Liabilities

2022 2023 2024 2025
Cash 43.61 81.48 53.82 59.68
Receivables 0.11 0.98 3.22 2.42
Inventory — — — —
Other 11.45 12.07 9.47 8.90
55.16 94.53 66.51 71.00
2022 2023 2024 2025
Payables 10.14 19.74 21.68 10.32
ST’ Debt 4.85 — — —
Other 29.77 34.10 42.03 54.69
39.97 53.98 63.77 65.06
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
36.88
’24 — — — —
(7.78)
’23 — — — —
39.19
’22 — — — —
5.03
’21 — 0.01 — —
3.13
’20 — 0.04 — 0.02
2.87
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — (19.76) — (37.81)
(37.81)
’24 — (6.28) — (21.16)
(21.16)
’23 — (18.84) — (13.50)
(13.50)
’22 — (18.64) — (39.09)
(39.09)
’21 — (18.16) — (35.34)
(35.34)
’20 — (14.18) — (31.46)
(31.46)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — (19.94) — (38.42)
(38.43)
’24 — (6.81) — (22.07)
(22.07)
’23 — (19.19) — (13.86)
(13.87)
’22 — (18.73) — (39.19)
(39.19)
’21 — (18.22) — (35.61)
(35.62)
’20 — (14.24) — (31.57)
(31.58)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
(0.57)
’24 — — — —
(1.56)
’23 — — — —
(1.17)
’22 — (0.79) — (0.94)
(1.76)
’21 — (1.05) — (0.55)
(1.60)
’20 — (1.02) — (0.58)
(1.60)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡ 2.32 1.75 2.76 2.82 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 10.42 11.00 8.96 30.35 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 102 102 108 97 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.05 0.38 (0.07) 0.38 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.03 39.19 (7.78) 36.88 — — —
Revenue
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (60.09) (42.84) (73.62) (27.11) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,194.12%) (109.32%) 946.06% (73.51%) — — —
EBT Margin
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (60.10) (42.97) (73.73) (27.11) — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.58 1.64 1.75 1.69 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.14 1.06 (0.16) 0.77 — — —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ (1.76) (1.17) (1.56) (0.57) — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.12) (0.37) (0.45) (0.79) — — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 (0.01) (0.02) (0.01) — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.12) (0.38) (0.47) (0.80) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.82) (0.05) (1.50) (2.00) — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.85 36.93 47.27 47.82 — — —
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,674.87 3,318.15 1,295.66 10,437.49 — — —
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 — — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,799.02 3,079.38 1,321.93 10,407.60 — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.68) (3.53) (2.23) (12.45) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (39.09) (13.50) (21.16) (37.81) — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.10) (0.36) (0.92) (0.62) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (39.19) (13.87) (22.07) (38.43) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.20 40.55 2.74 5.93 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.56 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.96 (81.48) (53.82) (59.68) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (28.49) (1.99) (71.10) (95.58) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.55%) (52.21%) (84.46%) (36.24%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3,754.04%) 281.84% 201.73% 32.53% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Nanobiotix S.A. (NBTX), a leader in nanoparticle-enhanced cancer therapies, has ignited investor excitement with its NBTXR3 platform, designed to amplify radiotherapy for solid tumors like head-and-neck cancers. After languishing below $3 earlier in 2024, the stock has surged on pivotal clinical milestones, including Phase 3 interim data showing a 52% reduction in death risk, FDA fast-tracks, and a explosive 2023 revenue jump to €39.2 million—a 679% year-over-year surge fueled by collaborations and grants. High gross margins at 100% and disciplined operations (headcount steady around 100) underscore its efficient path toward commercialization, despite a 2024 revenue dip from lumpy milestones.

While profitability remains distant amid R&D investments, improving EBT margins (to 9.5% in 2024) and tightening cash burn signal progress, bolstered by a cash-rich balance sheet (negative net debt) providing runway for upcoming approvals and expansions into prostate and sarcoma trials. Valuation multiples have compressed favorably with revenue growth, and analysts project up to 29% upside, positioning NBTX for reacceleration in 2025-2027 amid a $10B+ radioenhancer market opportunity.

The bull case shines: strategic pivots, global partnerships unlocking €100M+ milestones, and a decade of innovation could deliver 5-10x returns if NBTXR3 disrupts oncology standards—though risks like trial setbacks loom. Dive into the full analysis for detailed financials, correlations, and catalysts driving this high-conviction growth story.

Read full commentary →

Nanobiotix S.A. - Sponsored ADR (NBTX) Latest News

News by impact score

Fine-tune

17 Sep

3 , 1:06 PM
Nanobiotix questions whether lung tumor control with its technology justifies risks from repeat radiation treatments. Analysis of risks versus benefits for Nanobiotix lung tumor approach may shift investor views on treatment viability.

14 Sep

4 , 2:00 AM
Nanobiotix announces completion of full cohort phase 1 results for JNJ-1900 (NBTXR3) in inoperable recurrent non-small cell lung cancer. Phase 1 completion for NBTXR3 in lung cancer advances the lead oncology candidate toward later trials and potential approval.

2 Jun

3 GlobeNewswire, 2:30 AM
Nanobiotix joins the Euronext Tech Leaders Index. Index inclusion can lift visibility and trading interest but does not alter operations or fundamentals.

30 May

4 Simply Wall St., 6:04 PM
Nanobiotix raises equity to fund JNJ-1900 progress amid volatile share rally. Equity financing directly supports JNJ-1900 advancement and may shift company trajectory and investor sentiment.

26 May

3 GlobeNewswire, 4:59 PM
Nanobiotix S.A. closed its global offering. Global offering closure supplies Nanobiotix with fresh capital to support its operations and development programs.

3 GlobeNewswire, 4:44 PM
Nanobiotix S.A. closed its global offering, completing the capital raise through ADSs and ordinary shares including full exercise of the underwriters' option. Closure of global offering delivers immediate capital infusion strengthening Nanobiotix balance sheet and operational runway.

22 May

3 GlobeNewswire, 4:15 PM
Nanobiotix fully exercises underwriters’ over-allotment option, raising total gross proceeds from the offering to approximately $100 million. Full exercise of over-allotment supplies Nanobiotix with roughly $100 million in additional cash to fund operations and development.

21 May

4 GlobeNewswire, 10:57 AM
Nanobiotix S.A. priced an oversubscribed €85m global offering. Oversubscribed €85m offering supplies substantial capital that can accelerate development programs and improve financial runway.

3 , 10:57 AM
Nanobiotix priced an oversubscribed €85m global offering of ordinary shares and American Depositary Shares, including a U.S. offering and an international private placement to institutional investors. Oversubscribed €85m raise supplies capital and signals demand but represents routine financing rather than a product or regulatory milestone.

20 May

4 Investor's Business Daily, 8:00 AM
Nanobiotix drew Wall Street attention with its physics-based nanotechnology platform that enhances radiotherapy to treat solid tumors more effectively. Positive investor focus on Nanobiotix's core radiotherapy-enhancement technology can drive higher visibility, funding, and valuation.

3 , 6:19 PM
Nanobiotix launches a global follow-on offering of American Depositary Shares to raise additional capital for operations and development. Follow-on offering secures funding for Nanobiotix while causing share dilution that influences stock performance.

17 May

3 GlobeNewswire, 10:15 AM
Nanobiotix announced presentation of Part 1 data from a randomized Phase 2 trial evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer. Early clinical data readout for NBTXR3 in lung cancer may moderately shift near-term investor views on pipeline progress.

4 May

3 GlobeNewswire, 5:29 PM
Nanobiotix announces protocol amendment to its ongoing global Phase 3 head and neck cancer study. Protocol amendment to Phase 3 trial affects clinical development and approval prospects moderately.

20 Apr

3 , 2:30 AM
Nanobiotix announced new preclinical data showing pre-treatment with Nanoprimer technology improves systemic bioavailability and reduces toxicity for LNP-delivered DNA immunotherapy. Preclinical data highlights Nanoprimer's potential to enhance DNA immunotherapy delivery and safety, offering moderate innovation impact without clinical evidence.

1 Apr

3 www.marketbeat.com, 11:20 AM
Nanobiotix shared key highlights from its H2 earnings call, detailing financial results, operational updates, and forward-looking guidance for the period. H2 earnings call highlights offer moderately noticeable insights into financial performance and strategic outlook.

31 Mar

4 GlobeNewswire, 4:15 PM
Nanobiotix S.A. - Sponsored ADR (NBTX) provided a business update and reported full-year 2025 financial results. Full-year financial results combined with business updates represent major strategic and performance indicators that can significantly alter NBTX's trajectory and investor sentiment.

30 Mar

4 GlobeNewswire, 2:30 AM
Nanobiotix presented first data from a randomized Phase 2 clinical trial evaluating JNJ-1900 (NBTXR3) in Stage 3 inoperable lung cancer. First data from randomized Phase 2 trial in lung cancer marks a significant pipeline milestone with potential to drive stock volatility and investor interest.

17 Dec

3 GlobeNewswire, 4:15 PM
Nanobiotix S.A. announced updates regarding its voting rights and share capital. The company has made adjustments to its share structure, which may influence shareholder voting dynamics and overall governance. These changes are part of ongoing efforts to enhance corporate governance and align with market expectations. Changes in voting rights and share capital can moderately influence shareholder sentiment and governance but are not expected to drastically alter the company's trajectory.

15 Dec

3 GlobeNewswire, 2:30 AM
Nanobiotix S.A. will be included in the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective from December 18, 2023. This inclusion is expected to enhance the company's visibility and attract more investors, potentially leading to increased trading volumes and market interest. Inclusion in major indices is likely to improve market sentiment and visibility, but the overall impact on long-term performance may be limited.

8 Dec

4 , 2:06 AM
Nanobiotix S.A. has experienced a significant surge in share price over the past several months, prompting an assessment of its valuation. Analysts are evaluating the implications of this price increase on the company's future performance and market position, considering factors such as product development and competitive landscape. The substantial share price surge indicates potential strategic shifts and heightened investor interest that could significantly impact future performance.

24 Nov

4 GlobeNewswire, 4:15 PM
Nanobiotix S.A. provided an operational and financial update for the third quarter of 2025, highlighting key developments and outlining its clinical outlook for 2026. The company reported progress in its ongoing clinical trials and emphasized its commitment to advancing its innovative cancer therapies. Financial results showed a stable position, with investments directed towards research and development efforts aimed at enhancing product offerings and market presence. Significant advancements in clinical trials and strategic focus on innovative therapies are likely to impact future performance and investor sentiment.

4 www.fool.com, 10:29 AM
Nanobiotix S.A. (NBTX) has seen a remarkable 660% increase in stock value this year, driven by positive developments in its cancer treatment technology and promising clinical trial results. The company's innovative approach to enhancing the effectiveness of radiotherapy has garnered significant investor interest. Analysts suggest that ongoing advancements and potential partnerships could sustain this upward momentum, making NBTX a stock to watch in the biotech sector. The significant advancements in cancer treatment technology and positive clinical trial results are likely to impact investor sentiment and the company's future performance.

13 Nov

4 GlobeNewswire, 4:15 PM
Nanobiotix S.A. has announced advancements in its Curadigm Nanoprimer platform, outlining updated plans for both internal pipeline development and external collaborations. These developments aim to enhance the company's product offerings and strategic partnerships in the biotechnology sector. The advancements in the Curadigm Nanoprimer platform and plans for collaborations are likely to significantly impact Nanobiotix's future performance and market positioning.

4 Simply Wall St., 11:09 AM
Nanobiotix S.A. has secured a $71 million royalty deal that is expected to enhance its growth prospects. This agreement is anticipated to provide significant financial support, enabling the company to advance its innovative cancer therapies and expand its market presence. The deal is seen as a strategic move to bolster Nanobiotix's position in the competitive biopharmaceutical landscape. The $71 million royalty deal is a major strategic move that could significantly enhance Nanobiotix's growth and market positioning.

4 Simply Wall St., 4:14 AM
Nanobiotix S.A. secured $71 million in non-dilutive financing, leading to a 5.9% increase in its stock price. This funding is expected to support the company's ongoing clinical trials and development of its innovative cancer therapies. The financing is seen as a strategic move to enhance the company's financial stability and growth potential in the competitive biotech landscape. Securing significant non-dilutive financing is likely to enhance Nanobiotix's strategic position and investor sentiment.

31 Oct

4 GlobeNewswire, 3:00 AM
Nanobiotix S.A. has entered into a strategic royalty monetization agreement with Healthcare Royalty, potentially generating up to $71 million. This agreement is expected to extend the company's cash runway, supporting its long-term growth initiatives. The agreement significantly enhances financial resources, which could impact future growth and market positioning.

24 Oct

4 GlobeNewswire, 2:00 AM
Nanobiotix S.A. announced updates to its JNJ-1900 (NBTXR3) clinical program, following the transfer of sponsorship and operational control of an ongoing Phase 3 trial for head and neck cancer. This transition aims to enhance the trial's execution and oversight, potentially accelerating the development process for NBTXR3. The transfer of trial sponsorship and operational control is a significant strategic move that could enhance the development and market positioning of NBTXR3.

15 Oct

3 GlobeNewswire, 2:00 AM
Nanobiotix S.A. announced updates regarding its voting rights and share capital. The company has made adjustments to its share structure, which may influence shareholder voting dynamics and overall governance. These changes are part of ongoing efforts to enhance corporate governance and align with shareholder interests. Changes in voting rights and share capital can moderately influence shareholder sentiment and governance structure.

9 Oct

4 www.barchart.com, 10:40 AM
Nanobiotix S.A. Sponsored ADR (NBTX) has seen a remarkable 440% increase in stock price over the past year, raising questions about its sustainability as a potential long-term investment versus a temporary surge. The company is focused on developing innovative cancer therapies, and while its recent performance has attracted attention, analysts remain divided on its future prospects. Factors such as market competition, regulatory challenges, and the effectiveness of its products will play crucial roles in determining whether NBTX can maintain its momentum or if it will falter. The significant stock price increase indicates major investor interest and potential shifts in market dynamics that could impact future performance.

3 Oct

4 www.clinicaltrialsarena.com, 7:32 AM
Nanobiotix S.A. announced positive results from a Phase I trial of its treatment for oesophageal cancer, which is part of its ongoing research into head and neck squamous cell carcinoma (HNSCC). The trial demonstrated promising safety and efficacy, potentially positioning the company for future advancements in cancer therapies. This success may enhance investor confidence and support further development of Nanobiotix's innovative treatments. Positive trial results could significantly impact future product development and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us